Scientific Industries (SCND) Registration Filing summary

Company overview and business model

• Designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems for research use in universities, pharma, and industry.

• Operates two segments: legacy benchtop equipment (mixers, shakers, scales, pill counters) and bioprocessing systems (smart sensors, analytics, software).

• Bioprocessing segment is a strategic growth focus, with recent product launches and an acquisition to expand capabilities.

Financial performance and metrics

• Net loss of $1.78M for Q1 2025, $6.45M for 2024, and $9.09M for 2023; accumulated deficit of $35.7M as of March 2025.

• Q1 2025 revenues were $2.41M, down 3.1% year-over-year; 2024 revenues were $10.7M, down 3.6% from 2023.

• Gross margin for Q1 2025 was 42.2%; for 2024, 44.2% (down from 45.9% in 2023) due to higher costs.

• Cash and equivalents were $587,900 at end of 2024; negative cash flow from operations of $3.68M in 2024 and $1.33M in Q1 2025.

• Management expresses substantial doubt about ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; proceeds from warrant exercises will be used for working capital.

• Company intends to retain future earnings for business development and does not expect to pay dividends.